Subcutaneous low-dose interleukin-2 and intravenous 5-fluorouuacil plus high-dose levofolinic acid as salvage treatment for metastatic colorectal carcinoma

Anti-Cancer Drugs

Volumn 7, Issue 4, 1996, Pages 386-391

  Gebbia, Vittorio ^a   Testa, Antonio ^a   Majello, Evaristo ^b   Cannata, Giuseppe ^a   Tirrito, Maria Lina ^a   Mastrandrea, Gluseppe ^a   Feo, Mario ^a   Bajardi, Guido ^a   Colucci, Giuseppe ^b   Gebbia, Nicolò ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

5 Fluorouracil; Interleukin 2; Levofolinic acid

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; LOPERAMIDE; OCTREOTIDE; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; DISEASE DURATION; DRUG RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SALVAGE THERAPY;

EID: 9344244774     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199606000-00002     Document Type: Article

References (33)

1. Bruckner HW, Motwani BT. Chemotherapy of advanced cancer of the colon and rectum. Semin Oncol 1991; 18: 443-361.
2. Kreuser ED, Wadler S, Thiel E. Interactions between cytokines and cytotoxic drugs: putative molecular mechanisms in experinetal hematology and oncology. Semin Oncol 1991; 19 (suppl 4): 1-7.
3. Wadler S, Schawrz EL, Goldman M, et al. Fluorouracil and recombinant alpha-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1769-5.
4. Pazdur R, Adjani J, Patt YZ, Winn R, Jackson D, Shepard B. Phase II study of fluorouracil and recombinant interferon alpha-2A in previously untreated advanced colorectal carcinoma. J Clin Oncol 1990; 8: 2027-31.
5. Kemeny N, Younis A, Seiter K, Kellsen D, Derby S, Sammarco P. Combination of fluorouracil (FU) and recombinant alpha interferon in advanced colorectal carcinoma: activity but significant toxicity. Cancer 1990; 66: 2470-5.
6. Legha SS, Buzaid AC. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. Semin Oncol 1993; 20: 27-32.
7. Khayat D, Borel C, Tourani JM, et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alpha-2a for metastatic melanoma. J Clin Oncol 1993; 11: 2173-80.
8. Stahl M, Wilke HJ, Seeber S, Schmoll HJ. Cytokines and cytotoxic agents in renal cell carcinoma: a review. Semin Oncol 1992; 19 (suppl 4): 70-9.
9. Figlin RA, Pierce WC, Belldegrun A. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma. Semin Oncol 1993; 20 (suppl 6): 11-5.
10. Cuturi MC, Anegon L, Sherman F, et al. Production of hematopoietic colony stimulating factors by human natural killer cells. J Exp Med 1989; 169: 323-30.
11. Robertson M, Ritz J. Biology and clinical relevance of natural killer cells. Blood 1990; 76: 2331-438.
12. Heslop HE, Gottlieb DJ, Bianchi ACM, et al. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous bone marrow transplantation. Blood 1989; 74: 1374-80.
13. Heslop HE, Duncombe AS, Reittie JE, et al. Interleukin-2 infusion induces haemopoietic growth factors and modify marrow regeneration after chemotherapy or autologous marrow transplantation. Br J Haematol 77: 237.
14. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl J Med 1987; 316: 889-905.
15. Gautham SC, Chikkala NF, Ganapathi R, Hamilton TA. Combination therapy with adriamycin and interleukin-2 augments immunity against murine renal cell carcinoma. Cancer Res 1991; 51: 6133-7.
16. Papa MZ, Yang JC, Vetto JT, Shiloni E, Eisenthal A, Rosenberg SA. Combined effects of chemotherapy and interleukin-2 in therapy of mice with advanced pulmonary tumors. Cancer Res 1988; 48: 122-9.
17. Heys SD, Franks CR, Eremin O. Interleukin-2 therapy: current role in surgical oncology practice. Br J Surg 1993; 80: 155-62.
18. Hamblin TJ, Williamson PJ, Goerge DK. A phase II study of r-IL-2 and 5FU chemotherapy in the treatment of metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 1990; 9: 112.
19. Markowitz A, Yeomans A, Freiman J. Phase I study of recombinant interferon-alpha-2a (rIFN), recombinant interleukin-2 (r-IL-2) and 5-fluorouracil in gastrointestinal malignances. Proc Am Soc Cliu Oncol 1990; 9: 119.
20. Palmer PA, Atzpodien J, Philip T, et al. A comparison of 2 modes of administration of recombinat interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma. Cancer Biotherapy 1993; 8: 123-36.
21. Buter J, Sleijfer DT, van der Graaf WTA, de Vries EGE, Willemse PHB, Mulder NH. A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2. Semin Oncol 1993; 20: 16-21.
22. Caligiuri MA. Low dose recombinant interleukin-2 therapy: rationale and potential clinical applications. Semin Oncol 1993; 20 (suppl 9): 3-10.
23. Keyomarsi K, Moran RG. Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res 1986; 46: 5229-35.
24. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
25. Miller AB, Hoogstraten B, Staquet M, Winkler M. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
26. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up and a follow-up trial of a new chemotherapeutic agent. J Chron Dis 1961; 13: 346-53.
27. Gebbia V, Valenza R, Testa A, et al. Weekly levofolinic acid and 5-fluorouracil plus hydroxyurea in metastatic gastrointestinal adenocarcinomas. Am J Clin Oncol 1994; 17: 485-489.
28. Yasumoto K, Ogura T. Intrapleural application of recombinant interleukin-2 in patients with malignat pleurisy due to lung cancer. Biotherapy 1991; 3: 345-9.
29. Lissoni P, Barni S, Ardizola A, et al. Intracavitary administration of interleukin-2 as palliative therapy for neoplastic effusions. Tumori 1992; 78: 118-20.
30. Hamblin TJ, Inzani V, Sadullah S, et al. A phase II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients in metastatic colorectal carcinoma. Cancer Treat Rev 1989; 16 (suppl 1): 163-7.
31. Madajewic S, Petrelli N, Rustum Y, et al. A phase I-II trial of high dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res 1984; 44: 4667-8.
32. Laufman LR, Krzeczowski KA, Roach R, Segal M. Leucovorin plus 5-fluorouracil: an effective treatment for metastatic colorectal cancer. J Clin Oncol 1987; 5: 1394-400.
33. Heys SD, Eremin O, Ruggeri EM, et al. A phase III study of recombinant inteleukin-2, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal carcinoma. Eur J Cancer 1995; 31A: 19-25.